Recent Finacing
Recent Raise
Sojournix is a clinical-stage Waltham, Massachusetts pharmaceutical company developing SJX-653, a selective NK3 receptor antagonist as a once-daily non-hormonal treatment for moderate-to-severe menopausal vasomotor symptoms, currently in Phase 1.
